All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 163 points (-1.0%) at 16,122 as of Thursday, Oct. 1, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,041 issues advancing vs. 1,943 declining with 144 unchanged.

The Health Services industry currently sits down 1.5% versus the S&P 500, which is down 0.7%. A company within the industry that increased today was Abbott Laboratories ( ABT), up 0.5%. On the negative front, top decliners within the industry include Abiomed ( ABMD), down 3.5%, Cooper Companies ( COO), down 2.2%, Intuitive Surgical ( ISRG), down 1.9%, Waters ( WAT), down 1.5% and Baxter International ( BAX), down 1.2%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Health Services industry higher today. As of noon trading, Grifols is up $0.34 (1.1%) to $30.74 on heavy volume. Thus far, 342,949 shares of Grifols exchanged hands as compared to its average daily volume of 417,100 shares. The stock has ranged in price between $30.40-$31.03 after having opened the day at $30.95 as compared to the previous trading day's close of $30.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. Grifols has a market cap of $10.4 billion and is part of the health care sector. The company has a P/E ratio of 30.0, above the S&P 500 P/E ratio of 23.7. Shares are down 10.8% year-to-date as of the close of trading on Wednesday. Currently there is 1 analyst who rates Grifols a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Grifols Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, CR Bard ( BCR) is up $1.00 (0.5%) to $187.32 on average volume. Thus far, 385,809 shares of CR Bard exchanged hands as compared to its average daily volume of 599,000 shares. The stock has ranged in price between $185.78-$188.59 after having opened the day at $187.66 as compared to the previous trading day's close of $186.31.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. CR Bard has a market cap of $13.8 billion and is part of the health care sector. The company has a P/E ratio of 41.2, above the S&P 500 P/E ratio of 23.7. Shares are up 11.8% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate CR Bard a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates CR Bard as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full CR Bard Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Edwards Lifesciences ( EW) is up $1.40 (1.0%) to $143.57 on heavy volume. Thus far, 837,207 shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $140.63-$144.98 after having opened the day at $140.63 as compared to the previous trading day's close of $142.17.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $14.8 billion and is part of the health care sector. The company has a P/E ratio of 34.5, above the S&P 500 P/E ratio of 23.7. Shares are up 11.6% year-to-date as of the close of trading on Wednesday. Currently there are 12 analysts who rate Edwards Lifesciences a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Edwards Lifesciences as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Edwards Lifesciences Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).